Lantheus Holdings, Inc. Announces Public Offering of 5,200,000 Shares of Common Stock
September 08 2016 - 4:14PM
Business Wire
Lantheus Holdings, Inc. (“Lantheus” or the “Company”)
(NASDAQ:LNTH), today announced an agreement to sell 5,200,000
shares of its common stock to Credit Suisse and Jefferies LLC as
underwriters in an underwritten public offering pursuant to an
effective shelf registration statement filed with the Securities
and Exchange Commission (the “SEC”) on Form S-3. The Company
intends to use a combination of net proceeds from this offering,
together with cash on hand, to pay down approximately $55 million
of the outstanding principal balance under its senior secured
credit facilities. Credit Suisse and Jefferies LLC will act as
underwriters for the offering.
A shelf registration statement (including a prospectus) relating
to the offering of common stock was filed with the SEC on August 5,
2016 and became effective on August 31, 2016. Before you invest,
you should read the prospectus included in that registration
statement and the documents incorporated by reference in that
registration statement as well as the prospectus supplement related
to this offering. You may obtain these documents for free by
visiting EDGAR on the SEC website at www.sec.gov. When available,
copies of the prospectus supplement and accompanying prospectus
related to the offering may also be obtained by contacting Credit
Suisse Securities (USA) LLC., Attn: Prospectus Department, One
Madison Avenue, New York, NY 10010, or by calling (800) 221-1037,
or by emailing newyork.prospectus@credit-suisse.com or by
contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by calling (877) 547-6340, or by emailing
Prospectus_Department@Jefferies.com.
The offering of these securities will be made only by means of a
prospectus supplement and the accompanying prospectus.
This release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction. Any offer to buy the securities may be
withdrawn or revoked, without obligation or commitment of any kind,
at any time prior to notice of its acceptance given after the
effective date of the shelf registration statement.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging,
Inc.Lantheus Holdings, Inc. is the parent company of Lantheus
Medical Imaging, Inc. (“LMI”), a global leader in the development,
manufacture and commercialization of innovative diagnostic imaging
agents and products. LMI provides a broad portfolio of products,
which are primarily used for the diagnosis of cardiovascular
diseases. LMI’s key products include the echocardiography contrast
agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable
Suspension; TechneLite® (Technetium Tc99m Generator), a
technetium-based generator that provides the essential medical
isotope used in nuclear medicine procedures; and Xenon (Xenon Xe
133 Gas), an inhaled radiopharmaceutical imaging agent used to
evaluate pulmonary function and for imaging the lungs. LMI is
headquartered in North Billerica, Massachusetts with offices in
Puerto Rico and Canada.
Safe HarborThis press release includes statements that
express our opinions, expectations, beliefs, plans, objectives,
assumptions or projections regarding future events or future
results and therefore are, or may be deemed to be, “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including statements regarding the offering.
These forward-looking statements can generally be identified by the
use of forward-looking terminology, including the terms
“anticipates,” “intends,” “plans,” “seeks,” “believes,”
“estimates,” “expects,” “should,” “could,” “predicts,” “targets,”
“hopes” or, in each case, their negatives or other variations or
comparable terminology. By their nature, forward-looking statements
involve risks and uncertainties because they relate to events and
depend on circumstances that may or may not occur in the future,
including risks and uncertainties relating to the consummation of
the proposed offering by the Company and the risks identified, or
incorporated by reference, in the prospectus supplement or
accompanying prospectus.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160908006638/en/
Lantheus Holdings, Inc.Meara Murphy, 978-671-8508
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Apr 2023 to Apr 2024